SARS COV2 vaccine ResPonse In Obesity - SCORPIO study

保护人们免受新冠肺炎感染的最好方法是接种疫苗。疫苗会触发人的免疫系统，因此如果人再次接触病毒，免疫系统就会做好有效反应的准备。重要的是要知道，引起新冠肺炎的SARS-CoV-2病毒疫苗对有潜在健康状况的人是否像对健康人一样有效。这项研究的目的是测试SARS-CoV-2疫苗在有体重问题和糖尿病的人身上是否同样有效。超重/肥胖的人和患有糖尿病的人如果感染新冠肺炎，更有可能患重病。如果疫苗不起作用，那么当英国有1,000万人认为自己受到保护时，他们仍将面临感染新冠肺炎的高风险。通过将肥胖/糖尿病和感染/免疫领域的世界领先医生和研究人员聚集在一起，该研究项目将确定超重或患有糖尿病的人的免疫反应是否不同。之前对流感疫苗等其他疫苗的研究表明，有这些健康状况的人的免疫反应可能会更弱，或者持续的时间可能不会那么长。我们认为，一些肥胖/糖尿病患者的免疫反应很可能很弱，我们想看看减肥是否能提高疫苗反应。如果是这样的话，这将为减肥治疗提供额外的帮助和支持，目前只有少数几十年来一直在与体重作斗争的人才能获得这些治疗。在接下来的一年里，我们将邀请200名正在接受不同减肥治疗(高强度饮食和手术)的人参加天蝎座的研究，这是他们日常医疗护理的一部分。如果他们同意，我们将额外采集一些血液样本，看看他们的疫苗反应在减肥治疗后是否发生了变化。我们将收集有关他们的身高和体重、健康状况的信息，并详细查看免疫系统、血糖水平和荷尔蒙。根据我们的经验，很可能有些人会减去少量体重，而另一些人则会减去很多。研究减肥对第一针、第二针新冠肺炎疫苗免疫应答的影响。我们将密切关注研究中的患者在定期门诊期间的情况，如果他们出现新冠肺炎感染的症状，我们将确保他们得到及时的医疗救治。我们还将安排基因测序，以了解病毒的特定变种是否正在影响有体重问题和糖尿病的人。我们将把这些结果与当地的正常体重人群进行比较，并与全国各地的同事进行比较，以最大限度地利用现有信息。在研究结束时，我们将确定肥胖/糖尿病患者的免疫反应是否较弱，哪些人群是最危险的(例如，血糖最高的人群？)并找出减肥是否能迅速提高对疫苗的免疫反应，让人们对新冠肺炎有更好的保护。

The best way to protect people from COVID-19 is by vaccination. Vaccines trigger a person's immune system so it is primed to respond efficiently if the person comes into contact with the virus again. It is important to know whether vaccines against the SARS-CoV-2 virus, which causes COVID-19, work as well in people with underlying health conditions as they do in healthy people. The aim of this study is to test whether the SARS-CoV-2 vaccine works equally well in people with weight problems and diabetes. People who are overweight/obese and those who have diabetes are much more likely to become seriously ill if they develop COVID-19 infection. If vaccines don't work as well, then 10 million people in the UK will still be at high risk of COVID-19 infection, when they think they are protected. By bringing together world-leading doctors and researchers in obesity/diabetes and infection/immunity, this research project will establish whether the immune response is different in people who are overweight or have diabetes. Previous research with other vaccines such as the flu vaccine, suggests that the immune response might be weaker or may not last as long in people with these health conditions. We think it is likely that some people with obesity/diabetes will have a weak immune response and we want to see if losing weight can boost the vaccine response. If it does, then this would provide a strong incentive for extra help and support for weight loss treatments, which are currently only available to a small number of people who have really struggled with their weight for decades. Over the next year, we will invite 200 people who are having different weight loss treatments (intense diet and surgery) as part of their routine medical care to take part in the SCORPIO study. If they agree, we will take a few extra blood samples to look at whether their vaccine response changes after weight loss treatment. We will collect information about their height and weight, medical conditions and look in detail at the immune system, blood sugar levels and hormones. Based on our experience, it is likely some people will lose a small amount of weight while others will lose a lot of weight. We will study the impact of weight loss on the immune response to the first and second dose of the COVID-19 vaccine. We will keep a close eye on people in the study during their regular clinic visits and if they develop symptoms of COVID-19 infection, we will ensure they receive prompt medical care. We will also arrange for genetic sequencing to see if particular variants of the virus are affecting people with weight problems and diabetes.We will compare these results with normal weight people based locally and compare these results with colleagues around the country to make best use of the available informationAt the end of the study, we will establish whether the immune response is weaker in people with obesity/diabetes, which groups of people are most at risk (e.g. is it people with the highest blood sugars?) and find out if weight loss can rapidly improve the immune response to the vaccine, giving people better protection against COVID-19.